DP-QB-PSA-005
AXP000242.1 · Phage therapy
- Platform
- phage cocktail (five phages)
- Sponsor
- Ottawa Hospital Research Institute
Names
| Name | Type | Source |
|---|---|---|
| DP-QB-PSA-005 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Pseudomonas aeruginosa bacteriophage (five-phage cocktail)
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07698002 | "Debridement PhagE AnTibiotics for PJI" | Not yet recruiting | Phase 2/3 | 2026-07-02 | 2027-08-01 | 10 | Periprosthetic Infection |
Recent changes
No changes recorded in its trials yet.
Notes
Five-phage cocktail against Pseudomonas aeruginosa, used with DP-QB-STA-005 in a phase 2/3 feasibility trial in periprosthetic joint infection treated by DAIR (NCT07698002). Manufacturer not taken from a primary source.
How to cite
DP-QB-PSA-005 (AXP000242.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000242.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.